Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients

J Thromb Haemost. 2003 Oct;1(10):2252-3. doi: 10.1046/j.1538-7836.2003.00442.x.
No abstract available

Publication types

  • Letter

MeSH terms

  • Acenocoumarol / administration & dosage
  • Acenocoumarol / therapeutic use*
  • Alleles
  • Anticoagulants / administration & dosage
  • Anticoagulants / therapeutic use*
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Cytochrome P-450 CYP2C9
  • Gene Frequency
  • Genotype
  • Humans
  • Italy
  • Polymerase Chain Reaction
  • Thromboembolism / genetics*
  • Thromboembolism / prevention & control
  • Warfarin / administration & dosage
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Warfarin
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • Acenocoumarol